Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT-004 gene therapy in adults with hemophilia B
CTR20232648Phase 2Suspended
- Sponsor
- Frontera Therapeutics
- Start
- Sep 2023
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of FT-004 in hemophilia B (HB), sponsored by Frontera Therapeutics. Started Sep 2023; status: suspended.
02
Drugs
FT-004
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20232648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232648.